Yahoo Finance

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), ...
Yahoo Finance

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
Nasdaq

Recursion Acquires Full Ownership of ENPP1 Inhibitor Program REV102 from Rallybio for Hypophosphatasia Treatment

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.
The Motley Fool

Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...
TheServerSide

Recursion vs Iteration: What's the difference?

Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...